The anti-inflammatory effects of statins have likely not been used to their fullest extent,
particularly in reducing venous thromboembolic events. Current therapy for thrombotic …

Introduction: Acute pulmonary embolism is the third leading cause of cardiovascular death.
Management options include anticoagulation with or without thrombolysis. Concurrent …

Introduction Patients with acute pulmonary embolism (APE) who present with right
ventricular dysfunction (RVD) have a worse prognosis. This study aimed to evaluate the …

To evaluate the feasibility and the efficacy of computed tomography pulmonary angiography
(CTPA) in differentiating acute pulmonary embolism (PE) patients with or without right …

Intermediate-risk pulmonary embolism (PE), also known as submassive PE, occurs in a
substantial group of patients and carries a significant mortality risk. With adequate risk …

A marine fibrinolytic compound FGFC1 enhancing fibrinolysis was obtained involving
enzymatic kinetic parameters of a reciprocal activation system with a single chain urokinase …

АКТУАЛЬНОСТЬ Преимущества тромболитической терапии перед антикоагулянтной в
лечении острой легочной эмболии неопределенны. Цель исследования Провести …

Results: Statistical significance was demonstrated in several parameters comparing pre-and
post-scores. Mean Likert scores of perceptions of self-efficacy increased by 0.70 (pre= 3.40 …

目的探讨急性肺栓塞(APE) 患者右心功能不全(RVD) 的相关预测指标. 方法选取2013 年7 月-
2016 年9 月于中国医科大学附属盛京医院确诊的符合纳入排除标准的APE 患者127 例 …

Пулмоналната емболија (ПЕ) е една од најчестите кардиоваскуларни причини за
морталитет. Поради неспецифичната клиничка слика која варира во широк распон од …